13252-84-1Relevant articles and documents
Discovery and characterization of aminopiperidinecoumarin melanin concentrating hormone receptor 1 antagonists
Kym, Philip R.,Iyengar, Rajesh,Souers, Andrew J.,Lynch, John K.,Judd, Andrew S.,Gao, Ju,Freeman, Jennifer,Mulhern, Mathew,Zhao, Gang,Vasudevan, Anil,Wodka, Dariusz,Blackburn, Christopher,Brown, Jim,Che, Jennifer Lee,Cullis, Courtney,Lai, Su Jen,LaMarche, Matthew J.,Marsilje, Tom,Roses, Jon,Sells, Todd,Geddes, Brad,Govek, Elizabeth,Patane, Michael,Fry, Dennis,Dayton, Brian D.,Brodjian, Sevan,Falls, Doug,Brune, Michael,Bush, Eugene,Shapiro, Robin,Knourek-Segel, Victoria,Fey, Thomas,McDowell, Cathleen,Reinhart, Glenn A.,Preusser, Lee C.,Marsh, Kennan,Hernandez, Lisa,Sham, Hing L.,Collins, Christine A.
, p. 5888 - 5891 (2005)
4-(1-Benzo[1,3]dioxol-5-ylmethylpiperidine-4-ylmethyl)-6-chlorochromen-2- one (7) is a potent, orally bioavailable melanin concentrating hormone receptor 1 (MCHr1) antagonist that causes dose-dependent weight loss in diet-induced obese mice. Further evalu
TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS
-
Paragraph 0321-0322, (2021/07/17)
The present invention discloses a series of tricyclic compounds and use thereof in preparing a medicament for treating a disease related to CRBN protein. Specifically, the present invention discloses a derivative compound of formula (1) or a pharmaceutically acceptable salt thereof.
Synthesis and biological evaluation of bis-N2,N2′-(4-hydroxycoumarin-3-yl)ethylidene]-2,3-dihydroxysuccinodihydrazides
Hoppe, Heinrich C.,Isaacs, Michelle,Kaye, Perry T.,Krause, Rui W. M.,Manyeruke, Meloddy H.,Seldon, Ronnett,Tshiwawa, Thendamudzimu,Warner, Digby F.
, (2020/01/22)
A series of N2,N2′-bis[4-hydroxycoumarin-3-yl)ethylidene]-2,3-dihydroxysuccino-hydrazides, containing 4-hydroxycoumarin, hydrazine and tartaric acid moieties, have been prepared and examined for possible biological activity. Several of these compounds exhibit promising HIV-1 integrase inhibition (IC50 = 3.5 μM), and anti-T. brucei (32% viability) and anti-mycobacterial (Visual MIC90 = 15.63 μM) activity.
